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Abstract 
Th e syn th esis o f a series o f α-L-2'-deoxythreofuranosyl nucleosides featuring the 
nucleobases A, T, C and U is described in seven steps from 1,2-O-isopropyledene-α-L-
threose, involving a Vorbrüggen coupling and a Barton-McCombie deoxygenation 
protocol as the key steps. All analogues, including a phosphoramidate nucleoside 
phosphate prodrug of the T analogue, were evaluated against a broad panel of different 
viruses but found inactive, while also lacking notable cellular toxicity. The thymidine 
analogue showed inhibition to mitochondrial thymidine kinase-2 (TK-2), herpes simplex 
virus type 1 (HSV-1) TK, varicella-zoster virus (VZV) TK and M. tuberculosis 
thymidylate kinase.  
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Introduction 
The human immunodeficiency virus (HIV) epidemic has fostered research on antiviral 
drugs both in academia and industry [1]. Although preventive vaccines are available for a 
number of viral diseases, the chances of successfully developing a safe and effective 
vaccine for HIV and hepatitis C virus (HCV) in the near future looks very uncertain 
[2]. 
Recently, Herdewijn and coworkers showed that selected L-2-deoxythreose nucleoside 
phosphonates (I; Figure 1) selectively inhibit HIV without affecting human DNA 
synthesis [6]. PMDTA (Ia) and PMDTT (Ib) lack a hydroxymethyl group at the 4'-
position of the furanose ring, but instead have a phosphonomethyl ether moiety at the 3'-
position, which mimicks the monophosphate ester of a 3’-hydroxymethyl substituent.  
Structural modifications on either the sugar or base moiety of natural nucleosides has 
resulted in a series of 24 nucleoside or nucleotide analogues licensed as drugs against 
various viral infections, such as herpes simplex virus (HSV), human cytomegalovirus 
(HCMV), varicella zoster virus (VZV), HIV-1, human hepatitis B virus (HBV) and HCV 
[3-5]. Despite this achievement, continued efforts toward the discovery of new 
nucleoside-based antivirals are required to overcome common problems in antiviral 
chemotherapy, such as toxicity, adverse effects, drug-drug interactions and, last but not 
least, the development of drug resistance. 
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These nucleoside analogues require two additional phosphorylation steps by cellular 
kinases before they are incorporated in the viral genome and lead to chain termination of 
the proviral DNA strand during the reverse transcription process.  
By synthesizing and evaluating the isomeric analogues of PMDTA, the importance of the 
relative (cis) and absolute orientation of the substituents at the 1' and 3'- positions has 
been demonstrated to be crucial for antiviral activity [6b]. Also, it was shown that 
homologation of the 3'-O-phosphonomethyl group of Ia-b to a phosphonoethyl was at the 
expense of the biological activity [6c]. Most likely, this loss of activity results from the 
poor acceptance of these homologues as substrates by kinases required for conversion to 
their metabolic diphosphate form. Noteworthy, in 2000 Eschenmoser and coworkers 
showed that (L)-α-threofuranosyl oligonucleotides (TNAs) containing vicinally 
connected (3'→2') phosphodiester bridges undergo informational base pairing  in 
antiparallel strand orientation and are capable of cross-pairing with RNA and DNA [7]. 
Inspired by the promising anti-HIV-1/HIV-2 activity of Ia-b, we decided to explore the 
synthesis and the antiviral properties of the corresponding non-phosphonylated 2-
deoxythreose-based nucleoside analogues II, characterized by a four-carbon-only 
carbohydrate part. We expected that due to the absence of the 4'-hydroxymethyl group, 
the secondary 3'-OH could become accessible for phosphorylation by cellular nucleoside 
kinases and anticipated IIa-d to have a superior bioavailability compared to the 
phosphonates. Remarkably, the synthesis of such α-L-2'-deoxythreofuranosyl analogues 
(exhibiting the 1'R, 3'R configuration) has not been reported before. 
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Results and Discussion 
Chemical Synthesis 
The synthesis of target compounds started from 1,2-O-isopropyledene-α-L-threose 1 
(Scheme 1), which was synthesized in multi-gram scale following literature 
procedures[8,9]. The hydroxyl group of 1 was protected using either benzyl bromide or 
4-methoxybenzyl (PMB) chloride to give compounds 2 and 3 in excellent yields. A 
benzyl group is a safe and versatile protecting group for carbohydrates, but may require 
harsh deprotection conditions. We also explored a more sensitive PMB protecting group, 
which may be removed under alternative conditions. Next, deprotection of the 
isopropylidene group upon treatment with 80% aq. acetic acid followed by acetylation 
afforded the key precursors 4 and 5 in good yield.  
A Vorbrüggen coupling reaction of 4 and 5 with the preformed silyl-protected 
nucleobases exclusively gave the α-nucleosides 6-11 due to anchimeric assistance from 
the 2-O-acetyl group [10]. The benzyl-protected thymine- and uracil-nucleosides 6 and 7 
were isolated in considerably better yields than the PMB protected analogues, due to 
instability of the PMB-protecting group under Vorbrüggen conditions. Moreover, the 
reaction between PMB-protected glycon 5 with silylated N6-benzoyladenine and N4-
acetylcytosine failed to produce the desired coupling products in acceptable yields, which 
forced us to restrict further investigations to the benzyl-protected nucleosides. Under 
normal coupling conditions, the yield of the adenine coupling product 10 was also very 
low, possibly due to the formation of other isomers [11]. However, prolonged reaction 
time at elevated temperature (50 °C) afforded the thermodynamically favored isomer 10 
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in an acceptable yield of 42%. Under the normal coupling conditions the cytidine 
analogue 11 was obtained in 70 % yield. 
The 2'-O-acetyl group of 6 and 7 was removed by treatment with 7N ammonia in 
methanol. Similar treatment of 8 and 9 led to the formation of small amounts of 2',3'-
dihydroxy analogues (10-15%). Lowering the ammonia concentration to 1N allowed to 
obtain the desired compounds 14 and 15 in high yields. Stirring compound 10 at room 
temperature in a 7N solution of ammonia in methanol for 2 days removed both the 2'-O-
acetyl and the N(6)-benzoyl group to yield 16. Likewise, 11 was deprotected to the 
dideacetylated compound 17, which was selectively N-acylated to 18 with one equivalent 
of acetic anhydride in dimethylformamide [12]. 
Deoxygenation of the 2'-hydroxy group was realized following a two step Barton-
McCombie procedure [13]. The xanthate was formed by reacting the 2'-OH group of 12-
16 and 18 with p-tolyl chlorothionocarbonate in the presence of 4-dimethylaminopyridine. 
The intermediate formed was subjected to heating with tributyltinhydride and 
azoisobisbutyronitrile in toluene to give the 2'-deoxygenated compounds 19-24 in 
moderate to good yields (47-86%). 
All target compounds were obtained after debenzylation. However, optimal 
debenzylation procedures were distinct for each analogue. The 2'-deoxythreose thymine 
and uracil analogues 25 and 26 could be obtained by catalytic hydrogenation of 19 and 20 
in good albeit variable yields, possibly due to catalyst poisoning by the residual sulphur 
from the previous deoxygenation reaction. Desulphurization with hydrogen over Raney-
Nickel prior to palladium-catalysed debenzylation improved the reproducibility of this 
step. Alternatively, CAN-mediated deprotection [14] of 21 and 22 afforded 25 and 26, 
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respectively. The adenine analogue 27 was obtained by a palladium-catalysed 
hydrogenation reaction in moderate yields.  
The cytosine analogue 29 was obtained via two different routes. After an unsuccessful 
attempt to hydrogenate 24, the benzyl group was removed by treatment with excess of 
dichlorodicyanoquinone (DDQ) in dichloromethane at 50 °C in a sealed reaction vial for 
3 days [15]. This method gave 28 in a disappointing yield of 11%. Hence, we also 
explored the transformation of the uridine analogue 26 to compound 29 (Scheme 2) [16]. 
This was realized by protecting the 3'-hydroxy group of 26 to the corresponding acetate 
30, which was subsequently treated with phosphorous oxychloride and 1,2,4-triazole, 
bubbling ammonia gas and a 7N solution of ammonia in methanol. 
The coupling between the phenyldichlorophosphate (31) and L-alanine benzyl ester 
tosylate (32) has been performed in the presence of Et3N (2 eq) giving the desired 
product (33) as an oil, which was used in the following step as a crude (Scheme 3). The 
final coupling of the nucleoside 25 has been performed using an excess of the 
phosphorochloridate (33) (3 eq) in the presence of tBuMgCl (3eq) following the 
procedure reported by Uchiyama [17] and extensively used for the synthesis of the 
ProTides [18]. The desired compound 34 was obtained as a mixture of two 
diastereoisomers confirmed by the presence of two peaks in the 31P NMR (2.92, 2.27). 
 
Pharmacological Activity 
None of the final nucleoside analogues showed cytotoxicity at 100 µg/mL. No anti-HIV-
1 and anti-HIV-2 activity was observed in human T-lymphocyte (CEM) cells (EC50 
>100 µg/mL). Furthermore, no significant activity could be detected against the 
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following viruses: human cytomegalovirus (HEL), varicella-zoster virus (VZV) (HEL); 
influenza A (H1N1 &H3N2) and B virus (MDCK), feline corona & feline herpes virus 
(CRFK); herpes simplex virus type 1 (HSV-1), HSV-2, vesicular stomatitis virus (VSV) 
and vaccinia virus (HEL); Coxsackie virus B4 and respiratory syncytial virus (HeLa); 
para-Influenza virus-3, reovirus-3, Sindbis virus and Punta Toro virus (Vero). Since the 
lack of antiviral activity could be due to the inability of virally-induced and/or cellular 
enzymes to active the nucleoside analogues, a nucleoside monophosphate prodrug was 
prepared from compound 25 (Scheme 3). Such prodrug may intracellularly release the 
free monophosphorylated form according to a multistep process lined-out in Scheme 4. 
However, also the phosphoramidate 34 failed to show activity against HIV-1, HIV-2, 
HSV-1, HSV-2, vaccinia virus, vesicular stomatitis virus and HSV-1 (TK-
 
). 
Enzymatic study using carboxypeptidase Y enzyme. 
The first step of the bioactivation of the phosphoramidate ProTide moiety involves the 
hydrolysis of the ester moiety which is supposed to be mediated by a carboxypeptidase-
type enzyme (Scheme 4). An enzymatic study using carboxypeptidase Y enzyme has 
been performed in order to understand whether compound 34 may be metabolized under 
these conditions. 
The experiment was performed by incubating compound 34 with carboxypeptidase in 
acetone-d6 and trizma buffer (pH = 7.6) following its conversion by 31P-NMR. The 
spectra (Figure 2) showed a fast conversion of one of the diasteroisomers 34 (δP = 2.38) 
to the compound 37 (δP = 6.25) through the intermediate 35 (δP = 3.66). The other 
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diastereoisomer (δP = 2.24) was slower converted and it was still detectable after 14 h. 
This experiment showed that 34 is partially converted to the metabolite 37. 
 
Interaction of test compounds with nucleoside kinases. 
Interestingly, upon evaluation of their capacity to inhibit thymidine (1 µM) 
phosphorylation by recombinant purified human cytosolic TK1, human mitochondrial 
TK2, HSV-1 TK, VZV TK, and Drosophila melanogaster (Dm) dNK (Table 1), 
compound 25 proved inhibitory to TK-2, HSV-1 TK, and VZV TK at an IC50
In conclusion, we have developed a practical and straightforward procedure for the 
synthesis of a series of α-L-2'-deoxythreofuranosyl nucleosides containing four natural 
nucleobases. None of the analogues displayed significant antiviral activity or cytotoxicity. 
In an effort to bypass the first activation (phosphorylation) step of the nucleoside 
 ranging 
between 14 and 91 µg/mL and M. tuberculosis thymidylate kinase with a Ki of 18 µM. 
Therefore, compound 25 was investigated more in detail. Whereas 75% of the natural 
substrate thymidine (100 µM) was converted to its 5'-mono- (and 5'-di)phosphate within 
5 minutes upon exposure to HSV-1 TK, no signs of any conversion of compound 25 to its 
phosphorylated derivative was observed after 60 minutes of incubation with the enzyme. 
Therefore, we may assume that these nucleosides purely act as enzyme inhibitors, rather 
than acting as alternative substrates. Lineweaver-Burk kinetic analysis revealed a non-
competitive mechanism of inhibitory action of compound 25 against HSV-1 TK using 
dThd as the natural substrate (Figure 3). The inhibitory potential of some of the test 
compounds opens perspectives for using this L-α-2'-deoxythreofuranosyl ring as a 
scaffold for optimizing these enzyme inhibitory activities.  
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analogues, a phosphoramidate nucleoside phosphate prodrug was synthesized for 
compound 25, but this prodrug still lacked any measurable antiviral activity. However, 
the thymine analogue showed encouraging inhibitory activity towards a number of 
thymidine kinases, which may be a new starting point towards more potent and selective 
nucleoside kinase inhibitors. 
Experimental Section 
Chemical Synthesis 
All reagents were from standard commercial sources and of analytic grade. Dry solvents 
were obtained directly from commercial sources and stored on molecular sieves. 
Moisture sensitive reactions were carried out under argon atmosphere. Precoated Merck 
silica gel F254 plates were used for TLC, spots were examined under ultraviolet light at 
254 nm and further visualized by sulphuric acid-anisaldehyde spray. Column 
chromatography was performed on silica gel (63-200 μm, 60 Å, Biosolve, Valkenswaard, 
The Netherlands). NMR spectra were determined using a Varian Mercury 300 MHz 
spectrometer. Chemical shifts are given in ppm (δ) relative to the residual solvent signals 
or TMS as internal standard. Exact mass measurements were performed on a Waters LCT 
PremierXETMTime of flight (TOF) mass spectrometer equipped with a standard 
electrospray ionization (ESI) and modular LockSpray TM interface. Samples were 
infused in a CH3
(3aR,6S,6aR)-6-(benzyloxy)-tetrahydro-2,2-dimethylfuro[2,3-d][1,3]dioxole (2). To a 
solution of compound 1 (2.3 g, 14.36 mmol) in dry DMF (50 mL) cooled at 0 °C under 
inert atmosphere, NaH (60% in mineral oil, 0.861 g, 21.54 mmol) was added portionwise 
CN/water (1:1) mixture at 10 μL/min. 
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and the mixture was stirred for 10 minutes. Benzyl bromide (2.56 mL, 21.54 mmol) was 
added dropwise to the above suspension, which was allowed to come to room 
temperature and stirred for an additional 4h. The reaction mixture was quenched by 
addition of methanol (1 mL) and the volatile solvents were evaporated under reduced 
pressure. The residue was partitioned between water-ethyl acetate (1:3, 300 mL). The 
organic layer was separated, washed with water, brine and dried over anhydrous MgSO4. 
After evaporation, the crude product was purified by silica-gel chromatography (15% 
EtOAc-hexanes) to afford compound 2 (3.1 g, 87%) as a colorless oil. 1H NMR(CDCl3, 
300 MHz): δ 1.32 (s, 3H), 1.47 (s, 3H), 4.01-4.05 (m, 3H), 4.57 (s, 2H), 4.61 (d, J = 3.77 
Hz, 1H), 5.96 (d, J = 3.76 Hz, 1H), 7.27-7.39 (m, 5H). 13C NMR (CDCl3, 75 MHz): δ 
26.15, 26.71, 70.27, 71.09, 81.81, 82.84, 105.44, 111.46, 127.59, 127.80, 128.41, 137.32. 
ESI-HRMS for [C14H18O4 + NH4]+ 
(3aR,6S,6aR)-6-(4-methoxybenzyloxy)-tetrahydro-2,2-dimethylfuro[2,3-
d][1,3]dioxole (3). Compound 1 (1.5 g, 9.4 mmol) was reacted with NaH (60% in 
mineral oil, 0.45 g, 11.24 mmol) and p-methoxybenzylchloride (1.5 mL, 11.24 mmol) as 
described for synthesis of 2 to afford compound 3 (2.2 g, 84%) as a white low melting 
solid. 
calcd, 268.1549; found, 268.1565. 
1H NMR (CDCl3, 300MHz): δ 1.31 (s, 3H), 1.46 (s, 3H), 3.78 (s, 3H), 3.98-4.02 (m, 
3H), 4.48 (s, 3H), 4.58 (d, J = 3.76 Hz, 1H), 5.94 (d, J = 3.76 Hz, 1H), 6.87 (d, J = 8.72 
Hz, 2H), 7.24 (d, J = 8.77 Hz, 2H). 13C NMR (CDCl3, 75 MHz): δ 26.15, 26.71, 55.16, 
70.28, 70.78, 81.45, 82.87, 105.42, 111.42, 113.82, 129.27, 129.34, 159, 30. ESI-HRMS 
for [C15H20O5 + K]+
(3R,4S)-4-(benzyloxy)-tetrahydro-2, 3-furanyl diacetate (4). A solution of 2 (2.0 g, 8 
mmol) in 80% aq. acetic acid (40 mL) was stirred at 80 °C for 8 h. The reaction mixture 
 calcd, 319.0942; found, 319.0937. 
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was evaporated to give the crude intermediate as syrup. This syrup was dissolved in 
pyridine (30 mL) and treated with acetic anhydride (7.5 mL, 80 mmol). The solution was 
stirred at room temperature for 4h. The solvent was removed under vacuum and the 
resulting residue was purified by silica-gel column chromatography (20% EtOAc-
hexanes) to yield 4 (1.9 g, 81%) as a low melting solid. α,β anomeric ratio 3:2. 1H NMR 
(CDCl3, 300MHz): δ 1.98, 2.00, 2.02, 2.03 (s’s, 6H), 3.78-4.29 (m, 3H), 4.43-4.71 (m, 
2H), 5.13-5.19 (m, 1H), 6.06-6.32 (s & d, J = 4.51 Hz, 1H), 7.20-7.32 (m, 5H). ESI-
HRMS for [C15H18O6 + K]+ 
(3R,4S)-4-(4-methoxybenzyloxy)-tetrahydro-2,3-furanyl diacetate (5). Employing the 
procedure described above on 2.2 g of compound 3 resulted in 1.6 g (63% yield) of 
compound 5 as a white solid. α,β anomeric ratio 1:1. 
calcd, 333.0735; found, 333.0738. 
1H NMR (CDCl3, 300MHz): δ 2.04, 
2.07, 2.08, 2.09 (s’s, 6H), 3.79 (s, 3H), 3.82-4.32 (m, 3H), 4.42-4.68 (m, 2H), 5.17-5.24 
(m, 1H), 6.11, 6.37 (2d’s, J = 4.49, 2.39 Hz, 1H), 6.83-6.91 (m, 2H), 7.20-7.30 (m, 2H). 
ESI-HRMS for [C16H20O7 + Na]+
General condition for Vorbrüggen coupling reaction: The nucleobase (protected in 
case of adenine and cytosine) (1.2 eq.) was suspended in hexamethyldisilazane (50 eq.) 
containing trimethylsilyl chloride (0.7 eq.) and pyridine (10 eq.). The mixture was heated 
at reflux overnight. After cooling, the reaction mixture was evaporated and dried under 
high vacuum. The silylated nucleobase and the diacetate compound 4 or 5 (1 eq.) were 
dissolved in dry 1,2-dichloroethane (7 mL/mmol), and trimethylsilyl triflate (1.2 eq) was 
added dropwise at 0 °C. The clear solution was stirred for 4h at room temperature. The 
reaction mixture was diluted with dichloromethane (50 mL/ mmol) and washed with 
saturated aqueous NaHCO
 calcd, 347.1101; found, 347.1112. 
3. The organic layer was dried over anhydrous MgSO4 and 
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evaporated. Purification of the residue by silica-gel column chromatography (1% MeOH-
dichloromethane) afforded the pure coupling product as a white foam.  
(2R,3R,4S)-4-(benzyloxy)-tetrahydro-2-(3,4-dihydro-5-methyl-2,4-dioxopyrimidin-
1(2H)-yl)furan-3-yl acetate (6). Following the general reaction conditions a Vorbrüggen 
coupling between 4 and thymine afforded the title compound (1.07 g, 87%) 1H NMR 
(CDCl3, 300MHz): δ 1.72 (d, J= 1.19 Hz, 3H), 2.12 (s, 3H), 4.00-4.1 (m, 2H), 4.32 (app- 
dm, J= 8.75 Hz, 1H), 4.63 (app- dd, J= 14.68, 11.48 Hz, 2H), 5.22 (s, 1H), 6.08 (d, J= 
1.36 Hz, 1H), 7.22-7.34 (m, 5H), 7.37 (d, J= 1.22 Hz, 1H), 9.42 (brs, 1H). 13C NMR 
(CDCl3, 75 MHz): δ 12.57, 21.03, 71.81, 73.74, 79.93, 80.88, 89.41, 110.94, 128.17, 
128.47, 128.83, 136.41, 136.89, 150.69, 164.23, 169.90. ESI-HRMS for [C18H20N2O6 + 
H]+
(2R,3R,4S)-4-(benzyloxy)-tetrahydro-2-(3,4-dihydro-2,4-dioxopyrimidin-1(2H)-
yl)furan-3-yl acetate (7). Vorbrüggen coupling between 4 (500 mg, 1.7 mmol) and 
uracil (230 mg, 2.04 mmol) afforded 481 mg of the uridine analogue 7 (82 % yield). 
 calcd, 361.1400; found, 361.1399. 
1H 
NMR (CDCl3, 300MHz): δ 2.07 (s, 3H), 3.96 (d, J= 3.78 Hz, 1H), 4.02 (dd, J= 10.25, 
3.81 Hz, 1H), 4.24 (d, J= 10.28 Hz, 1H), 4.56 (app-q, J= 11.76 Hz, 2H), 5.17 (s, 1H), 
5.55 (dd, J= 8.19, 1.77 Hz, 1H), 5.96 (d, J= 1.18 Hz, 1H), 7.17-7.32 (m, 5H), 7.48 (d, J= 
8.20 Hz, 1H), 8.93 (brs, 1H). 13C NMR (CDCl3, 75 MHz): δ 21.03, 71.88, 74.27, 79.72, 
80.52, 89.82, 102.23, 128.28, 128.54, 128.87, 136.80, 140.58, 150.39, 163.39, 169.79. 
ESI-HRMS for [C17H18N2O6 + H]+
(2R,3R,4S)-4-(4-methoxybenzyloxy)-tetrahydro-2-(3,4-dihydro-5-methyl-2,4-
dioxopyrimidin-1(2H)-yl)furan-3-yl acetate (8). Vorbrüggen coupling between 5 (600 
 calcd, 347.1238; found 347.1246. 
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mg, 1.85 mmol) and thymine yielded 420 mg of the title compound (58 %). 1H NMR 
(CDCl3, 300MHz): δ 1.68 (d, J= 1.21 Hz, 3H), 2.07 (s, 3H), 3.73 (s, 3H), 3.98 (dd, J= 
14.17, 3.72 Hz, 2H), 4.14-4.25 (m, 1H), 4.50 (app-q, J= 14.14 Hz, 2H), 5.15 (m, 1H), 
6.00 (d, J= 1.34 Hz, 1H), 6.80 (d, J= 8.72 Hz, 2H), 7.14 (d, J= 8.78 Hz, 2H), 7.31 (d, J= 
1.24 Hz, 1H), 8.76 (brs, 1H). 13C NMR (CDCl3, 75 MHz): δ 12.60, 21.05, 55.54, 71.48, 
73.85, 79.87, 80.53, 89.45, 110.83, 114.21, 128.95, 129.88, 136.50, 150.48, 159.84, 
163.97, 169.87. ESI-HRMS for [C19H22N2O7 + H]+
(2R,3R,4S)-4-(4-methoxybenzyloxy)-tetrahydro-2-(3,4-dihydro-2,4-dioxopyrimidin-
1(2H)-yl)furan-3-yl acetate (9). Vorbrüggen coupling between 5 (325 mg, 1.0 mmol) 
and uracil yielded compound 9 (180 mg, 47%).
 calcd, 391.15; found, 391.1521. 
 1H NMR (CDCl3, 300MHz): δ 2.12 (s, 
3H), 3.79 (s, 3H), 4.00 (d, J= 3.73 Hz, 1H), 4.07 (dd, J= 10.24, 3.81 Hz, 1H), 4.27 (d, J= 
10.23 Hz, 1H), 4.55 (app-q, J= 12.73 Hz, 2H), 5.23 (s, 1H), 5.62 (dd, J= 8.21, 1.47 Hz, 
1H), 6.02 (d, J= 1.03 Hz, 1H), 6.86 (d, J= 8.81 Hz, 2H), 7.19 (d, J= 8.79 Hz, 2H), 7.54 (d, 
J= 8.21 Hz, 1H), 9.36 (brm, 1H). 13C NMR (CDCl3, 75 MHz): δ 21.00, 55.50, 71.42, 
74.32, 79.61, 80.15, 89.76, 102.16, 114.20, 128.91, 129.99, 140.68, 150.71, 159.80, 
164.03, 169.85. ESI-HRMS for [C18H20N2O7 + H]+
(2R,3R,4S)-2-(6-(benzamido)-9H-purin-9-yl)-4-(benzyloxy)-tetrahydrofuran-3-yl 
acetate (10). To a suspension of N
 calcd, 377.1343; found 377.1369. 
6-benzoyladenine (1.0 g, 4.08 mmol) in 
hexamethyldisilazane (35 mL, 0.17 mol) was added trimethylsilyl chloride (0.3 mL, 2.38 
mmol) and pyridine (2.7 mL, 34 mmol). The mixture was heated at reflux overnight. 
After cooling it was evaporated and dried under high vacuum. The silylated nucleobase 
and the diacetate 4 (1.0 g, 3.4 mmol) were dissolved in dry 1,2-dichloroethane (20 mL) 
and trimethylsilyl triflate (0.74 mL, 4.08 mmol) was added dropwise at 0 °C. The clear 
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solution was stirred at 50 °C for 24h. After dilution with dichloromethane (250 mL), the 
reaction mixture was washed with saturated aqueous NaHCO3. The organic layer was 
dried over anhydrous MgSO4 and evaporated. purification of the residue by silica-gel 
flash column chromatography (60 % EtOAc – hexanes) afforded pure 10 (0.68 g, 42%) as 
white foam.1H NMR (CDCl3, 300MHz): δ 2.08 (s, 3H), 4.04 (d, J= 3.76 Hz, 1H), 4.31 
(dd, J= 10.34, 3.89 Hz, 1H), 4.4 - 4.52 (m, 3H), 5.48 (s, 1H), 6.71 (s, 1H), 7.00 - 7.10 (m, 
5H), 7.31 – 7.50 (m, 3H), 8.08 (s, 1H), 8.12 – 8.19 (m, 2H), 8.59 (s, 1H). 13C NMR 
(CDCl3, 75 MHz): δ 21.03, 72.12, 76.07, 79.94, 80.49, 93.07, 127.81, 128.08, 128.16, 
128.22, 128.56, 128.74, 129.89, 132.32, 136.84, 137.81, 142.01, 143.61, 148.71, 169.68, 
175.13. ESI-HRMS for [C25H23N5O5 + H]+
(2R,3R,4S)-4-(benzyloxy)-tetrahydro-2-(4-(acetylamino)-2-oxopyrimidin-1(2H)-
yl)furan-3-yl acetate (11). A Vorbrüggen coupling reaction between N
 calcd, 474.1772; found, 474.1698. 
4-acetylcytosine 
and compound 4 (295 mg, 1.0 mmol) yielded compound 11 (270 mg, 70%). 1H NMR 
(CDCl3, 300MHz): δ 2.11 (s, 3H), 2.28 (s, 3H), 4.01 (d, J= 3.77 Hz, 1H), 4.20 (dd, J= 
10.31, 3.86 Hz, 1H), 4.35 (d, J= 10.25 Hz, 1H), 4.97 (app-q, J= 13.94 Hz, 2H), 5.28 (s, 
1H), 5.34 (s, 1H), 6.05 (s, 1H), 7.14 - 7.20 (m, 2H), 7.25 – 7.32 (m, 3H), 7.34 (d, J= 7.61 
Hz, 1H), 7.89 (d, J= 7.57 Hz, 1H), 10.34 (brs, 1H). 13C NMR (CDCl3, 75 MHz): δ 21.10, 
25.10, 71.67, 75.25, 79.15, 80.15, 91.22, 96.48, 128.21, 128.37, 128.77, 136.84, 145.07, 
155.25, 163.53, 169.70, 171.44. ESI-HRMS for [C19H21N3O6 + H]+
1-((2R,3R,4S)-4-(benzyloxy)-tetrahydro-3-hydroxyfuran-2-yl)-5-methylpyrimidine-
2,4(1H,3H)-dione (12). The 2'-O-acetylated nucleoside 6 (580 mg, 1.6 mmol) was 
treated with 7N methanolic ammonia solution (15 mL) at room temperature overnight. 
 calcd, 388.1503; 
found, 388.1509 
 15 
Evaporation yielded a residue which was purified by column chromatography (2% 
MeOH-CH2Cl2) to afford compound 12 (420 mg, 82 %) as a white foam.1H NMR 
(CDCl3, 300MHz): δ 1.67 (d, J= 0.75 Hz, 3H), 4.07 (s, 1H), 4.30 (s, 2H), 4.42 (s, 3H), 
5.59 (brs, 1H), 7.78 (s, 1H), 7.06-7.24 (m, 5H), 7.30 (d, J= 1.14 Hz, 1H), 10.60 (brs, 
1H). 13C NMR (CDCl3, 75 MHz): δ 12.24, 71.45, 74.97, 78.10, 82.20, 93.54, 109.38, 
127.59, 127.96, 128.45, 136.75, 136.92, 150.96, 164.73. ESI-HRMS for [C16H18N2O5 – 
H]-
1-((2R,3R,4S)-4-(benzyloxy)-tetrahydro-3-hydroxyfuran-2-yl)pyrimidine-
2,4(1H,3H)-dione (13). Following the procedure described for 12, compound 7 (475 mg, 
1.37 mmol) was hydrolysed to afford 13 (340 mg, 81%) as a white foam. 
 calcd, 317.1143; found 317.1147. 
1H NMR 
(CDCl3, 300MHz): δ 4.05 (s, 1H), 4.28 (s, 2H), 4.41 (s, 1H), 4.43 (s, 2H), 5.54 (dd, J= 
8.10, 1.81 Hz, 1H), 5.73 (s, 1H), 7.10-7.30 (m, 5H), 7.48 (d, J= 8.16 Hz, 1H), 10.52 (brs, 
1H). 13C NMR (CDCl3, 75 MHz): δ 71.85, 75.31, 82.29, 94.00, 101.32, 128.01, 128.37, 
128.79, 137.11, 140.94, 151.30, 164.38. ESI-HRMS for [C15H16N2O5 + H]+
1-((2R,3R,4S)-4-(4-methoxybenzyloxy)-tetrahydro-3-hydroxyfuran-2-yl)-5-
methylpyrimidine-2,4(1H,3H)-dione (14).
 calcd, 
305.1132; found, 305.1132. 
 Compound 8 (400 mg, 1.02 mmol) was 
treated with 1N methanolic ammonia solution (10 mL) at room temperature for 6h. 
Evaporation yielded a residue which was purified by column chromatography (2% 
MeOH-CH2Cl2) to afford compound 14 (280 mg, 78 %) as a white foam.1H NMR 
(CDCl3, 300MHz): δ 1.69 (d, J= 1.1 Hz, 3H), 3.71 (s, 3H), 4.03 (m, 1H), 4.27 (d, J= 1.84 
Hz, 2H), 4.35 (s, 2H), 4.40 (s, 1H), 5.76 (s, 1H), 6.76 (d, J= 8.72 Hz, 2H), 7.03 (d, J= 
8.70 Hz, 2H), 7.29 (d, J= 1.21 Hz, 1H),10.47 (brs, 1H). 13C NMR (CDCl3, 75 MHz): δ 
 16 
12.57, 55.54, 71.41, 75.15, 78.48, 82.24, 93.77, 109.64, 114.15, 129.30, 129.57, 137.02, 
151.20, 159.67, 164.92. ESI-HRMS for [C17H20N2O6 + H]+
1-((2R,3R,4S)-4-(4-methoxybenzyloxy)-tetrahydro-3-hydroxyfuran-2-yl)pyrimidine-
2,4(1H,3H)-dione (15). The ester moiety of 9 (180 mg, 0.48 mmol) was hydrolysed as 
described in the preparation of 14 to give compound 15 (145 mg, 90%) as white foam. 
 calcd, 349.1394; found, 
349.1389. 
1H 
NMR (CDCl3, 300MHz): δ 3.77 (s, 3H), 4.08-4.12 (m, 1H), 4.26-4.36 (m, 2H), 4.42 (s, 
2H), 4.46 (s, 1H), 5.55 (brs, 1H), 5.60 (dd, J= 8.14, 1.74 Hz, 1H), 5.79 (s, 1H), 6.83 (d, 
J= 8.77 Hz, 2H), 7.11 (d, J= 8.65 Hz, 2H), 7.53 (d, J= 8.19 Hz, 1H), 10.74 (brs, 1H). 13C 
NMR (CDCl3, 75 MHz): δ 55.52, 71.50, 75.44, 78.24, 82.05, 93.93, 101.26, 114.17, 
129.28, 129.69, 141.05, 151.40, 159.71, 164.51. ESI-HRMS for [C16H18N2O6 + H]+
(2R,3R,4S)-2-(6-amino-9H-purin-9-yl)-4-(benzyloxy)-tetrahydrofuran-3-ol (16). 
Nucleoside 10 (680 mg, 1.43 mmol) was treated with 7N methanolic ammonia solution 
(20 mL) at room temperature for 2 days. Evaporation yielded a residue which was 
purified by column chromatography (4% MeOH-CH
 
calcd, 335.1238; found, 335.1255. 
2Cl2) to afford compound 16 (450 
mg, 95 %) as a white foam. 1H NMR (DMSO-D6, 300MHz): δ 4.10 – 4.15 (m, 1H), 4.19 
(dd, J= 9.75, 4.72 Hz, 1H), 4.29 (dd, J= 9.72, 2.61 Hz, 1H), 4.57 (s, 2H), 4.66 – 4.71 (m, 
1H), 5.95 (d, J= 2.28 Hz, 1H), 6.02 (d, J= 4.52 Hz, 1H), 7.20 – 7.40 (m, 7H), 8.16 (s, 
2H). 13C NMR (DMSO-D6, 75 MHz): δ 75.82, 78.18, 82.47, 87.32, 95.55, 123.17, 131.76, 
131.96, 132.43, 141.20, 143.53, 152.62, 156.47, 159.74. ESI-HRMS for [C16H18N5O3 + 
H]+ calcd, 328.1404; found, 328.1419. 
 17 
4-amino-1-((2R,3R,4S)-4-(benzyloxy)-tetrahydro-3-hydroxyfuran-2-yl)pyrimidin-
2(1H)-one (17). The 2'-O-acetylated nucleoside 11 (210 mg, 0.54 mmol) was treated with 
7N methanolic ammonia solution (15 mL) at room temperature overnight. Evaporation 
yielded a residue which was purified by column chromatography (2% MeOH-CH2Cl2) to 
afford 140 mg of compound 17 (85% yield) as a white foam. 1H NMR (DMSO-D6, 
300MHz): δ 3.94 (app-d, J= 3.98 Hz, 1H), 4.10 (dd, J= 10.08, 4.06 Hz, 1H), 4.18 (d, J= 
4.28 Hz, 1H), 4.28 (d, J= 10.08 Hz, 1H), 4.47 (app-q, J= 11.70 Hz, 2H), 5.60 (d, J= 7.44 
Hz, 1H), 5.68 (d, J= 1.08 Hz, 1H), 5.75 (s, 1H), 5.80 (d, J= 4.35 Hz, 1H), 7.00 (brd, J= 
23.36 Hz, 2H), 7.19 – 7.26 (m, 2H), 7.26 – 7.35 (m, 3H), 7.53 (d, J= 7.41 Hz, 1H). 13C 
NMR (DMSO-D6, 75 MHz): δ 55.60, 70.91, 73.60, 78.12, 83.64, 93.06, 93.53, 128.18, 
128.34, 128.86, 138.44, 142.12, 155.94, 166.44. ESI-HRMS for [C15H17N3O4 + H]+
N-(1-((2R,3R,4S)-4-(benzyloxy)-tetrahydro-3-hydroxyfuran-2-yl)-1,2-dihydro-2-
oxopyrimidin-4-yl)acetamide (18). To a solution of compound 17 ( 180 mg, 0.59 mmol) 
in dry DMF (1.5 mL) was added acetic anhydride (56 µL, 0.59 mmol) and the mixture 
was stirred at room temperature for 24h. The residue obtained after distillation of the 
volatiles under reduced pressure, was purified by silica-gel column chromatography to 
give 18 (160 mg, 78%) as a white foam. 
 
calcd, 304.1292; found, 304.1294. 
1H NMR (CDCl3, 300MHz): δ 2.2 (s, 3H), 4.00 – 
4.04 (m, 1H), 4.23 (dd, J= 9.79, 1.48 Hz, 1H), 4.29 (dd, J= 9.93, 3.88 Hz, 1H), 4.39 (s, 
1H), 4.42 (s, 1H), 4.85 (brs, 1H), 5.73 (d, J= 0.75 Hz, 1H), 7.05 – 7.11 (m, 2H), 7.17 – 
7.25 (m, 3H), 7.31 (d, J= 7.50 Hz, 1H), 7.88 (d, J= 7.50 Hz, 1H), 9.36 (brs, 1H). 13C 
NMR (CDCl3, 75 MHz): δ 25.14, 71.68, 74.99, 78.65, 82.67, 94.89, 96.26, 127.96, 
 18 
128.17, 128.69, 137.25, 145.33, 156.17, 163.04, 171.17, 177.08. ESI-HRMS for 
[C17H19N3O5 + H]+
Barton – McCombie deoxygenation procedure for the synthesis of compounds 19 - 
24. To an ice-cold solution of compound 12 - 18 (1 eq.) and DMAP (2 eq.) in CH
 calcd, 346.1397; found, 346.1400. 
3CN 
(25 mL/mmol) was gradually added p-tolylchlorothionocarbonate (1.2 equivalents) at 
0 °C and stirring was continued at room temperature. After 2-4h the solvent was removed 
in vacuo and the residue was dissolved in ethyl acetate. The solution was washed twice 
with water, dried over anhydrous MgSO4
1-((2R,4R)-4-(benzyloxy)-tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-
dione (19). Deoxygenation of 12 (420 mg, 1.32 mmol) rendered 330 mg of compound 19 
in 82% yield. 
, filtered, and evaporated in vacuo to give the 
corresponding xanthate as yellow solid/syrup. The latter was dissolved in toluene (50 
mL/mmol), to which azobisisobutyronitrile (AIBN, 2 equivalent) was added. Tri-n-
butyltinhydride (2.5 equivalent) was added to this mixture at 60-70 °C, which was further 
stirred for 2-4 h at 95-100 °C. The solvent was removed in vacuo and the residue was 
purified by column chromatography (30-40 % EtOAc - hexanes) to yield the 2'-deoxy 
compound 19 – 24 as a foam. 
1H NMR (CDCl3, 300MHz): δ 1.69 (d, J= 1.19 Hz, 3H), 2.19 (ddd, J= 
15.07, 1.19, 0.88 Hz, 1H), (ddd, J= 15.11, 7.94, 5.45 Hz, 1H), 3.82 (dd, J= 10.27, 3.60 
Hz, 1H), 4.19 (dd, J= 5.47, 3.66 Hz, 1H), 4.30 (dd, J= 10.33, 1.50 Hz, 1H), 4.42 (app-dd, 
J= 15.15, 11.27 Hz, 2H), 6.17 (J= 7.88, 2.17 Hz, 1H), 7.16-7.32 (m, 5H), 7.47 (d, J= 1.22 
Hz, 1H), 8.67 (brs, 1H). 13C NMR (CDCl3, 75 MHz): δ 12.60, 38.49, 71.41, 74.51, 77.58, 
85.48, 110.35, 127.90, 128.32, 128.82, 136.98, 137.28, 150.76, 164.10. ESI-HRMS for 
[C16H18N2O4 + H]+ calcd, 303.1339; found, 303.1342.  
 19 
1-((2R,4R)-4-(benzyloxy)-tetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione (20). 
Deoxygenation of 13 (306 mg, 1.0 mmol) rendered 250 mg of compound 20 in 86% 
yield. 1H NMR (CDCl3, 300MHz): δ 2.23 (dm, J= 15.11 Hz, 1H), 2.39 (ddd, J= 15.11, 
7.56, 5.31 Hz, 1H), 3.85 (dd, J= 10.25, 3.67 Hz, 1H), 4.17 (app-t, J= 4.40 Hz, 1H), 4.28 
(dd, J= 10.24, 1.83 Hz, 1H), 4.41 (app-dd, J= 13.75, 11.63 Hz, 2H), 5.55 (dd, J= 8.16, 
1.73 Hz, 1H), 6.12 (dd, J= 7.54, 2.00 Hz, 1H), 7.14-7.34 (m, 5H), 7.61 (d, J= 8.16 Hz, 
1H), 8.86 (brs, 1H). 13C NMR (CDCl3, 75 MHz): δ 38.56, 71.39, 74.99, 77.28, 86.15, 
101.69, 127.96, 128.36, 128,85, 137.20, 141. 09, 150.70, 163.63. ESI-HRMS for 
[C15H16N2O4 + H]+
1-((2R,4R)-4-(4-methoxybenzyloxy)-tetrahydrofuran-2-yl)-5-methylpyrimidine-
2,4(1H,3H)-dione (21). Deoxygenation reaction of 14 (280 mg, 0.81 mmol) rendered 200 
mg of compound 21 in 75% yield. 
 calcd, 289.1183; found, 289.1183. 
1H NMR (CDCl3, 300MHz): δ 1.70 (d, J= 1.20 Hz, 
3H), 2.16 (ddd, J= 15.09, 2.04, 1.05 Hz, 1H), 2.40 (ddd, J= 15.1, 7.93, 5.52 Hz, 1H), 3.73 
(s, 3H), 3.80 (dd, J= 10.22, 3.66 Hz, 1H), 4.17 (app-t, J= 4.46 Hz, 1H), 4.28 (dd, J= 
10.26, 1.34 Hz, 1H), 4.35 (dd, J= 14.60, 11.00 Hz, 2H), 6.16 (dd, J= 7.90, 2.20 Hz, 1H), 
6.80 (d, J= 8.74 Hz, 2H), 7.12 (d, J= 8.74 Hz, 2H), 7.46 (d, J= 1.23 Hz, 1H), 8.69 (brs, 
1H). 13C NMR (CDCl3, 75 MHz): δ 12.65, 38.44, 55.55, 71.06, 74.57, 85.50, 110.28, 
114.21, 129.37, 129.56, 137.04, 150.79, 159.71, 164.16. ESI-HRMS for [C17H20N2O5 + 
H]+
1-((2R,4R)-4-(4-methoxybenzyloxy)-tetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-
dione (22). Deoxygenation of 15 (100 mg, 0.3 mmol) rendered 70 mg of compound 22 in 
74% yield. 
 calcd, 333.1445; found, 333.1461. 
1H NMR (CDCl3, 300MHz): δ 2.21 (app-dm, J= 15.15 Hz, 1H), 2.37 (ddd, J= 
15.03, 7.47, 5.28 Hz, 1H), 3.73 (s, 3H), 3.83 (dd, J= 10.20, 3.66 Hz, 1H), 4.25 (dd, J= 
 20 
10.14, 1.17 Hz, 1H), 4.33 (d, J= 1.40 Hz, 2H), 5.56 (d, J= 8.13 Hz, 1H), 6.11 (dd, J= 7.54, 
1.96 Hz, 1H), 6.80 (d, J= 8.70 Hz, 2H), 7.09 (d, J= 8.70 Hz, 2H), 7.61 (d, J= 8.13 Hz, 
1H), 9.21 (brs, 1H). 13C NMR (CDCl3, 75 MHz): δ 38.46, 55.53, 71.00, 75.06, 76.97, 
86.18, 101.67, 114.22, 129.28, 129.63, 141,24, 150.96, 159.70. ESI-HRMS for 
[C16H18N2O5 + H]+
9-((2R,4R)-4-(benzyloxy)-tetrahydrofuran-2-yl)-9H-purin-6-amine (23). 
Deoxygenation of 16 (450 mg, 1.38 mmol) rendered 200 mg of compound 23 in 47% 
yield. 
 calcd, 319.1294; found, 319.1295. 
1H NMR (DMSO-D6, 300MHz): δ 2.59 (dm, J= 14.60 Hz, 1H), 2.70 (ddd, J= 14.60, 
7.61, 5.84 Hz, 1H), 4.00 (dd, J= 9.88, 4.45 Hz, 1H), 4.25 (app-dt, J= 10.05, 1.30 Hz, 1H), 
4.41 (m, 1H), 4.54 (app-d, J= 2.42, 2H), 6.34 (dd, J= 7.55, 2.64 Hz, 1H), 7.24 (brs, 2H), 
7.26 – 7.38 (m, 5H), 8.24 (s, 1H), 8.22 (s, 1H). 13C NMR (DMSO-D6, 75 MHz): δ 37.32, 
70.30, 73.21, 77.47, 82.78, 118.52, 127.43, 127.53, 128.18, 137.87, 138.79, 149. 04, 152. 
47, 155.85. ESI-HRMS for [C16H17N5O2 + H]+
N-(1-((2R,4R)-4-(benzyloxy)-tetrahydrofuran-2-yl)-1,2-dihydro-2-oxopyrimidin-4-
yl)acetamide (24). Deoxygenation of 18 (190 mg, 0.55 mmol) rendered 100 mg of 
compound 24 in 56% yield. 
 calcd, 312.1455; found, 312.1469. 
1H NMR (CDCl3, 300MHz): δ 2.20 (s, 3H), 2.35 – 2.44 (m, 
2H), 3.98 (dd, J= 10.12, 3.72 Hz, 1H), 4.13 - 4.18 (m, 1H), 4.31 (s, 2H), 4.34 (dd, J= 
10.20, 0.96 Hz, 1H), 6.09 (dd, J= 6.08, 2.31 Hz, 1H), 7.06 – 7.12 (m, 2H), 7.21 (d, J= 
8.44 Hz, 1H), 7.20 – 7.28 (m, 3H), 7.91 (d, J= 7.50 Hz, 1H), 9.46 (brs, 1H). 13C NMR 
(CDCl3, 75 MHz): δ 25.06, 38.46, 71.08, 75.89, 77.20, 88.21, 96.20, 127.92, 128.19, 
128.76, 137.23, 145.37, 155.54, 163.35, 171.57. ESI-HRMS for [C17H19N3O4 + H]+ 
calcd, 330.1448; found, 330.1463. 
 21 
Deprotection method A. A solution of benzyl protected nucleoside in MeOH (40 
mL/mmol) was hydrogenated at atmospheric pressure for 5-24h in the presence of 10% 
Pd/C (150 mg/mmol). The catalyst was removed by filtration over a Celite path and the 
filtrate was concentrated in vacuo. The residue was purified by column chromatography 
(3% MeOH-CH2Cl2
Deprotection method – B. To a solution of benzyl protected nucleoside (1 eq.) in an 
acetonitrile-water (5:1) mixture (20 mL/mmol) at 0 °C ceric ammonium nitrate (CAN, 
2.5 equivalents) was added and stirring was continued for 1h. The reaction mixture was 
treated with solid NaHCO
) to isolate the desired product as a white amorphous solid. 
3 (2.0 g/mmol) followed by 25% MeOH-CH2Cl2 (50 
mL/mmol). The mixture was filtered over celite and washed with 25% MeOH-CH2Cl2 
(100 mL/mmol). The filtrate was concentrated in vacuum, and the residue was purified 
by column chromatography (3% MeOH-CH2Cl2
1-((2R,4R)-tetrahydro-4-hydroxyfuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione 
(25). 
) to isolate the final product as a white 
amorphous solid. 
Employing deprotection method A, 30 mg of title compound was obtained in 75 % yield 
from 19 (57 mg, 0.19 mmol), while method B afforded 80 mg of the same compound 
from 21 (150 mg, 0.45 mmol) in 84 % yield. 1H NMR (DMSO-D6, 300 MHz): δ 1.77 (d, 
J= 1.16 Hz, 3H), 1.87 (ddd, J= 14.49, 2.89, 1.52 Hz, 1H), 2.46 (ddd, J= 14.05, 8.07, 5.59 
Hz, 1H), 3.77 (dd, J= 9.37, 3.72 Hz, 1H), 3.98 (dt, J= 9.36, 1.41 Hz, 1H), 4.36 (brm, 1H), 
5.29 (d, J= 2.68 Hz, 1H), 6.05 (dd, J= 8.13, 2.72 Hz, 1H), 7.76 (d, J= 1.21 Hz, 1H), 11.23 
(brs, 1H). 13C NMR (DMSO-D6, 75 MHz): δ 13.06, 40.75, 69.54, 77.04, 85.32, 109.20, 
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137.79, 151.21, 164.54. ESI-HRMS for [C9H12N2O4 – H]- 
1-((2R,4R)-tetrahydro-4-hydroxyfuran-2-yl)pyrimidine-2,4(1H,3H)-dione (26). 
Employing deprotection method A, 43 mg of the title compound was obtained in 89% 
yield from 20 (70 mg, 0.24 mmol), while compound 22 (70 mg, 0.22 mmol) was 
converted to 34 mg of the title compound (78 % yield) using method B. 
calcd, 211.0724; found, 
211.0732. 
1H NMR 
(DMSO-D6, 300 MHz): δ 1.87 (ddd, , J= 14.53, 2.91, 1.88 Hz, 1H), 2.43 (ddd, J= 14.45, 
8.00, 5.48 Hz, 1H), 3.78 (dd, J= 9.43, 3.66 Hz, 1H), 3.97 (app-dt, J= 9.46, 1.25 Hz, 1H), 
4.34 (t, J= 4.23 Hz, 1H), 5.27 (brs, 1H), 5.60 (d, J= 8.05 Hz, 1H), 6.01 (dd, J= 8.00, 2.23 
Hz, 1H), 7.85 (d, J= 8.11 Hz, 1H), 11.19 (brs, 1H). 13C NMR (CDCl3, 75 MHz): δ 41.64, 
70.08, 78.56, 87.97, 100.61, 141.97, 150.95, 165.38. ESI-HRMS for [C8H10N2O4 + H]+
(3R,5R)-5-(6-amino-9H-purin-9-yl)-tetrahydrofuran-3-ol (27). Using method A with 
catalytic amount of acetic acid compound 23 (100 mg, 0.32 mmol) was converted to 29 
mg of compound 27 in 40 % yield. 
 
calcd, 199.0713; found, 199.072. 
1H NMR (DMSO-D6, 300MHz): δ 2.29 (ddd, J= 
14.44, 2.70, 1.54 Hz, 1H), 2.68 (ddd, J= 14.42, 8.24, 6.10 Hz, 1H), 3.91 (dd, J= 9.30, 
4.10 Hz, 1H), 3.97 (ddd, J= 9.32, 2.10, 1.06 Hz, 1H), 4.48 (m, 1H), 5.79 (d, J= 4.35 Hz, 
1H), 6.28 (dd, J= 8.27, 2.56 Hz, 1H), 7.28 (s, 2H), 8.15 (s, 1H), 8.36 (s, 1H). 13C NMR 
(DMSO-D6, 75 MHz): δ 40.86, 69.95, 76.98, 83.83, 119.53, 140.40, 149.53, 153.06, 
156.73. ESI-HRMS for [C9H11N5O2 + H]+
N-(1,2-dihydro-1-((2R,4R)-tetrahydro-4-hydroxyfuran-2-yl)-2-oxopyrimidin-4-
yl)acetamide (28). 2,3-Dichloro-5,6-dicyanobenzoquinone (DDQ, 770 mg, 3.4 mmol) 
 calcd, 222.0986; found, 222.0938. 
 23 
was added to a stirring solution of compound 24 (112 mg, 0.34 mmol) in dry 
dichloromethane (5.0 mL). The mixture was heated to 50 °C for 2 days in a sealed tube. 
Then it was sequentially treated with NaHCO3 (2.0 g), water (0.25 mL) and 20 mL of 1:1 
CH2Cl2-MeOH. After addition of anhydrous MgSO4 the resulting slurry was filtered. 
The filtrate was concentrated and purified by column chromatography (4-6% MeOH-
CH2Cl2) to afford 9 mg of compound 28 (11 % yield). 1H NMR (CDCl3, 300MHz): δ 
2.14 (s, 3H), 2.37 (ddd, J= 14.90, 7.02, 4.53 Hz, 1H), 2.61 (d, J= 14.90 Hz, 1H), 4.02 (dd, 
J= 9.80, 3.46 Hz, 1H), 4.28 (dd, J= 9.78, 1.14 Hz, 1H), 4.52 (t, J= 3.86 Hz, 1H), 5.94 (d, 
J= 6.56 Hz, 1H), 7.32 (d, J= 7.50 Hz, 1H), 8.03 (d, J= 7.48 Hz, 1H), 9.39 (brs, 1H). 13C 
NMR (CDCl3, 75 MHz): δ 25.12, 41.49, 70.28, 78.87, 89.48, 95.73, 146.47, 155.43, 
162.11, 170.95. ESI-HRMS for [C10H13N3O4 + H]+ calcd, 240.0979; found, 240.0982 & 
[2M + H]+
4-amino-1-((2R,4R)-tetrahydro-4-hydroxyfuran-2-yl)pyrimidin-2(1H)-one (29).  
 479.1936. 
Method 1. Applying the reaction conditions described for 12 on compound 28 (18 mg, 
75 µmol) gave 10 mg of compound 29 (67% yield) as an amorphous solid. 
Method – 2. To a stirring mixture of 1,2,4-triazole (223 mg, 3.24 mmol) in 5 mL of 
pyridine POCl3 (75 µL, 0.81 mmol) was added dropwise at room temperature. After 10 
minutes compound 30 (65 mg, 0.27 mmol) was added and stirring was continued for an  
additional 3h. After that time the reaction was bubbled with ammonia gas for 2h. Since 
TLC indicated that the deacetylation was not completed, the volatiles were removed and 
the residue treated with 7N methanolic ammonia (5 mL) for 5h. After evaporation the 
residue was purified by flash column chromatography (6% MeOH-CH2Cl2) to give 19 
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mg of the title compound 29 in 36% yield. 1H NMR (DMSO-D6, 300MHz): δ 1.82 (ddd, 
J= 14.28, 1.40, 1.10 Hz, 1H), 2.40 (ddd, J= 14.06, 7.87, 5.59 Hz, 1H), 3.81 (dd, J= 9.35, 
3.74Hz, 1H), 3.97 (dt, J= 9.31, 1.28 Hz, 1H), 4.33 (m, 1H), 5.16 (d, J= 2.76 Hz, 1H), 
5.69 (d, J= 7.42 Hz, 1H), 5.99 (dd, J= 7.83, 2.43 Hz, 1H), 7.08 (brd, J= 15.32 Hz, 2H), 
7.75 (d, J= 7.41 Hz, 1H). 13C NMR (DMSO-D6, 75 MHz): δ 41.48, 69.70, 77.26, 86.52, 
93.85, 142.46, 155.98, 166.37. ESI-HRMS for [C8H11N3O3 + H]+
(3R,5R)-tetrahydro-5-(3,4-dihydro-2,4-dioxopyrimidin-1(2H)-yl)furan-3-yl acetate 
(30). To a stirring solution of compound 26 (55 mg, 0.277 mmol) and 4-dimethyl 
aminopyridene (DMAP, 50 mg, 0.41 mmol) in 2 mL of DMF acetic anhydride (31 μL, 
0.33 mmol) was added. After stirring for 24h, the solvent was evaporated under vacuum 
and the residue was purified by column chromatography to isolate compound 30 (65 mg, 
97%). 
 calcd, 198.0873; 
found, 198.0876. 
1H NMR (CDCl3, 300MHz): δ 1.96 (s, 3H), 2.22 (ddd, J= 15.48, 2.74, 1.76 Hz, 
1H), 2.58 (ddd, J= 15.49, 7.24, 5.81 Hz, 1H), 4.04 (dd, J= 10.95, 3.87 Hz, 1H), 4.21 (ddd, 
J= 10.95, 1.60, 0.69 Hz, 1H), 5.31 (app-tt, J= 4.80, 0.84 Hz, 1H), 5.68 (d, J= 8.18 Hz, 
1H), 6.07 (dd, J= 7.21, 1.94 Hz, 1H), 7.45 (d, J= 8.18 Hz, 1H), 9.20 (brs, 1H). 13C NMR 
(CDCl3, 75 MHz): δ 21.24, 39.13, 72.88, 75.39, 86.61, 101.63, 139.77, 150.53, 163.72, 
170.19. ESI-HRMS for [C10H12N2O5 + H]+
Phenyl-(benzoxy-L-alaninyl)-phosphorochloridate (33). To a stirred solution of 
phenyldichlorophosphate 31 (0.30 mL, 2.00 mmol), L-alanine benzyl ester tosylate 32 
(0.43 g, 2.00 mmol) in anhydrous DCM (15 mL), was added dropwise under an Ar 
atmosphere at -78 oC anhydrous TEA (0.56 mL, 4.00 mmol). Following the addition the 
reaction mixture was stirred at -78 oC for 30 min, then at room temperature for 2 h. 
 calcd, 241.0819; found, 241.0830. 
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Formation of the desired compound was monitored by 31P NMR. After this period the 
solvent was removed under reduced pressure and the residue triturated with anhydrous 
diethyl ether. The precipitate was filtered under nitrogen and the solution was 
concentrated to give a yellow oil (87%, 0.62 g). 1H-NMR (CDCl3, 500 MHz): δ 7.33-7.28 
(10H, m, PhO, OCH2Ph), 5.15-5.13 (2H, m, OCH2Ph), 4.18-4.13 (1H, m, CHNH), 1.46-
1.44 (3H, m, CH3). 31P-NMR (CDCl3, 202 MHz): δ 7.86, 7.52. 
1-((2R,4R)-tetrahydro-4-hydroxyfuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione -
[ phenyl-(benzoxy-L-alaninyl)] phosphate (34). To a solution of 25 (0.093 g, 0.44 
mmol) in anhydrous THF (10 mL) was added 1.0M solution of tert-butyl magnesium 
chloride in THF (0.88 mL, 0.88 mmol) and the reaction mixture was stirred under an Ar 
atmosphere for 30 min. After this period, a solution of 33 (0.31 g, 0.88 mmol) in 
anhydrous THF (5 mL) was added dropwise and the reaction mixture was stirred at room 
temperature for 18 h. Then, 1.0M solution of tert-butyl magnesium chloride in THF (0.44 
mL, 0.44 mmol) and a solution of 32 (0.15 g, 0.44 mmol) in anhydrous THF (3 mL) was 
added and the stirring was continued for further 5 h. After this period, the solvent was 
removed and the residue was purified by column chromatography, gradient elution of 
DCM/MeOH = 98/2 then 96/4 to give a white solid (33%, 0.077 g). 1H-NMR (MeOD, 
500 MHz): δ 7.52 (0.5H, d, J = 1.2 Hz, H-6 of one diastereoisomer), 7.47 (0.5H, d, J = 
1.2 Hz, H-6 of one diastereoisomer), 7.38-7.30 (7H, m, PhO, OCH2Ph), 7.22-7.16 (2H, m, 
PhO, OCH2Ph), 7.12-7.10 (1H, m, PhO, OCH2Ph), 6.10 (0.5H, dd, J = 7.8 Hz, 2.3 Hz, H-
1’), 6.06 (0.5H, dd, J = 7.5 Hz, 1.8 Hz, H-1’), 5.21-5.17 (1H, m, H-3’), 5.16, 5.15 (2H, 2s, 
OCH2Ph), 4.45 (0.5H, dd, J = 10.8 Hz, 1.7 Hz, H-4’ of one diastereoisomer), 4.37 (0.5H, 
dd, J = 10.8 Hz, 1.7 Hz, H-4’ of one diastereoisomer), 4.03-3.92 (2H, m, H-4’, CHCH3), 
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2.63-2.55 (1H, m, H-2’), 2.32 (0.5H, d, J = 15.5 Hz, H-2’ of one diastereoisomer), 2.24 
(0.5H, d, J = 15.5 Hz, H-2’ of one diastereoisomer), 1.83 (1.5H, d, J = 1.1 Hz, 5-CH3 of 
one diastereoisomer), 1.82 (1.5H, d, J = 1.1 Hz, 5-CH3 of one diastereoisomer), 1.36 
(1.5H, d, J = 0.9 Hz, CHCH3 of one diastereoisomer), 1.34 (1.5H, d, J = 1.0 Hz, CHCH3 
of one diastereoisomer). 13C-NMR (MeOD, 125 MHz): δ 12.71 (5-CH3), 20.16 (d, JC–P = 
7.5 Hz, CHCH3), 20.33 (d, JC–P = 6.5 Hz, CHCH3), 40.51 (d, JC–P = 5.6 Hz, C-2’), 40.73 
(d, JC–P = 3.9 Hz, C-2’), 51.60, 51.84 (2s, CHCH3), 68.00, 68.04 (2s, OCH2Ph), 76.34 (d, 
JC–P = 4.0 Hz, C-4’), 76.79 (d, JC–P = 5.5 Hz, C-4’), 77.95 (d, JC–P = 5.2 Hz, C-3’), 77.99 
(d, JC–P = 4.9 Hz, C-3’), 86.95, 87.47 (2s, C-1’), 110.70, 111.03 (2s, C-5), 121.09, 121.14, 
121.18, 126.26, 126.29, 129.41, 129.43, 129.64, 129.65, 130.82, 130.92 (PhO, OCH2Ph), 
137.29 (‘ipso’ OCH2Ph), 137.77, 137.80 (2s, C-6), 152.03, 152.07, 152.12, 152.22, 
152.31 (C-2, (‘ipso’ OPh), 166.49, 166.55 (2s, C-4), 174.49 (d, JC–P = 4.6, COOCH2Ph), 
174.91 (d, JC–P = 4.1, COOCH2Ph). 31P-NMR (MeOD, 202 MHz): δ 2.92, 2.27. ES- MS= 
528.16 (M run on negative mode). HPLC = H2O/AcCN from 95/5 to 0/100 in 30 min = 
retention time 13.87, 14.19 min. 
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Antiviral Assays 
The antiviral assays [except anti-human immunodeficiency virus (HIV) assays] were 
based on inhibition of virus-induced cytopathicity in HEL [herpes simplex virus type 1 
(HSV-1), HSV-2 (G), vaccinia virus and vesicular stomatitis virus], Vero (parainfluenza-
3, reovirus-1, Sindbis, Coxsackie B4, and Punta Toro virus), or HeLa (vesicular 
stomatitis virus, Coxsackie virus B4, and respiratory syncytial virus) cell cultures. 
Confluent cell cultures in microtiter 96-well plates were inoculated with 100 cell culture 
inhibitory dose-50 (CCID50) of virus (1 CCID50 being the virus dose to infect 50% of the 
cell cultures). After a 1 h virus adsorption period, residual virus was removed, and the 
cell cultures were incubated in the presence of varying concentrations (200, 40, 8, … μM) 
of the test compounds. Viral cytopathicity was recorded as soon as it reached completion 
in the control virus-infected cell cultures that were not treated with the test compounds. 
The methodology of the anti-HIV assays was as follows: human CEM (
3 × 105 cells/cm3) cells were infected with 100 CCID50 of HIV-1(IIIB) or HIV-
2(ROD)/mL and seeded in 200 μL wells of a microtiter plate containing appropriate 
dilutions of the test compounds. After 4 days of incubation at 37 °C, HIV-induced CEM 
giant cell formation was examined microscopically. 
Enzymatic Assay 
Compound 34 (5.5 mg) was dissolved in d6-acetone (150 µL), and Trizma buffer (pH 7.6) 
(300 µL) was added. The resulting cloudy solution was placed in a NMR tube and a 31P-
NMR experiment at 25 °C was recorded as the blank experiment. Then a solution of 
carboxypeptidase Y (0.1 mg) in Trizma buffer (150 µL) was added and a 31P-NMR 
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experiment was performed recording the experiment every 5 min. 
Nucleoside Kinase Assay Using [CH3-3H]dThd as the Natural Substrate  
The activity of recombinant thymidine kinase 1 (TK-1), TK-2, herpes simplex virus-1 
(HSV-1) TK, varicella zoster virus (VZV) TK, and the multifunctional deoxynucleoside 
kinase (dNK) of Drosophila melanogaster and the 50% inhibitory concentration of the 
test compounds were assayed in a 50 μL reaction mixture containing 50 mM Tris/HCl, 
pH 8.0, 2.5 mM MgCl2, 10 mM dithiothreitol, 0.5 mM CHAPS, 3 mg/mL bovine serum 
albumin, 2.5 mM ATP, 1 μM [methyl-3H]dThd, and enzyme. The samples were 
incubated at 37 °C for 30 min in the presence or absence of different concentrations (5-
fold dilutions) of the test compounds. At this time point, the enzyme reaction still 
proceeded linearly. Aliquots of 45 μL of the reaction mixtures were spotted on Whatman 
DE-81 filter paper disks (Whatman, Clifton, NJ). The filters were washed three times for 
5 min each in 1 mM ammonium formate, once for 1 min in water, and once for 5 min in 
ethanol. The radioactivity was determined by scintillation counting. 
 
Supplementary Material: NMR spectra of the final compounds are available.  
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Table 1. Nucleoside kinase activity (IC50 in µg/mL) 
 TK-1 TK-2 HSV-1 TK  VZV TK  Dm dNK 
25  >200  91 ± 40  14 ± 3 26 ± 9 ≥ 200 
26  >200 60 ± 41 >200 >200 >200 
27  >200 >200 >200 >200 >200 
29  >200 >200 >200 >200 >200 
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Figure and Scheme Legends 
 
Scheme 1. Synthesis of α-L-2'-deoxythreofuranosyl nucleoside analogues 25-27 and 29. 
Reagents and conditions: (a) benzyl bromide, NaH, DMF, 0 °C→RT, 4h, 87%; (b) p-
methoxybenzyl chloride, NaH, DMF, -20 °C→RT, 4h, 84%; (c) i. 80% aq. 
CH3COOH, 80 °C, 8h; ii. Ac2O, pyridine, RT, 4h, 63-81%; (d) i. nucleobase, pyridine, 
TMSCl, HMDS, 135 °C, overnight; ii. silylated base, 4/5, TMSOTf, 1,2-
dichloroethane, 0 °C→RT, 3-5h, 45-87%; (e, for 10) i. nucleobase, pyridine, TMSCl, 
HMDS, 135 °C, overnight; ii. silylated base, 4/5, TMSOTf, 1,2-dichloroethane, 50 °C, 
24h, 42%; (f) 7N NH3-MeOH, RT, 4-6h, 81-95%; (g, for 14-15) 1N NH3-MeOH, RT, 
5h, 78-90%; (h) Ac2O, DMF, RT, 24h, 78%; (i) i. DMAP, O-(p-tolyl) 
chlorothionoformate, CH3CN, 0 °C →RT, 4h; ii. Bu3SnH, AIBN, toluene, 100 °C, 2-
4h, 47-86%; (j) Pd-C/H2, MeOH, RT, 3-8h, 40-89%; (k, on 21 and 22) CAN, 
CH3CN :H2O, 0 °C →RT, 1h, 78-84%; (l, for 28) DDQ, CH2Cl2, 50 °C, 72h, 11%. 
 
Scheme 2. An improved synthesis of the cytosine analogue 29. Reagents and conditions: 
(a) Acetic anhydride, DMAP, DMF, RT, 24h, 97%; (b) i. 1,2,4-triazole, POCl3, 
pyridine, RT, 4h; ii. NH3, 2h; iii. NH3-MeOH, RT, 5h, 36%. 
 
Scheme 3. Synthesis of the ProTide of 25. Reagents and conditions: (a) anhydrous TEA, 
anhydrous DCM, -78 oC for 30 min, rt, 2 h; (b) 1.0M tert-butylmagnesium chloride in 
THF, anhydrous THF, rt, 24 h. 
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Scheme 4. Putative mechanism of bioactivation of the ProTide. 
 
Figure 1. Structures of active L-2-deoxythreose nucleoside phosphonates (I) and the 
nucleoside surrogates of this study (II). 
 
Figure 2. Carboxypeptidase-mediated cleavage of compound 34, monitorated by 31P-
NMR. 
 
Figure 3. Lineweaver-Burk plot for compound 25. 
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Figure 1. 
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Figure 3. 
 
 
 
 
